| miR-30a-5p (41); miR-659-3p; mR-3917 |
Primary tumor with GC peritoneal metastasis |
Poor prognosis |
Unknown |
Diagnosis |
| miR-148-a (42); miR-26a (43,44) |
Plasma and GC tissue |
Tumor suppression |
FGF9 |
Biomarker; rescue invasion |
| miR-29 family (45) |
GC tissue |
Repress proliferation and metastasis |
CCND2 and matrix metalloproteinase-2 |
Monitoring tumor progression; miRNA-based therapeutics |
| miR-29a3p (46) |
GC cell lines |
Suppress GC metastasis |
HAS3 |
Potential therapeutic effector |
| miR-198 (47) |
GC tissue |
Inhibit tumor growth and promote GC apoptosis |
FGFR1 |
Diagnostic and therapeutic potential |
| miR140 (48) |
GC tissue |
Suppress GC proliferation and growth |
PD-L1 |
Potential effector in immunotherapeutics |
| miR-383 (49) |
GC cells |
Inhibit GC proliferation |
Cyclin E2 |
Candidate to interrupt GC progression |
| miR-30d-5p (50) |
non-small cell lung cancer |
Inhibit motility |
Cyclin E |
Tumor suppressor |
| miR-30a-5p (51) |
GC tissue and cell lines |
Inhibit GC growth and metastasis |
IGF-1R |
Potential therapeutic effector |
| miR-338-3p (52) |
GC tissue and cell lines |
Restrain tumor growth and dissemination |
PTP1B |
Tumor suppressor |
| miR-93-5p (53) |
GC tissue |
Repress GC growth dissemination |
IFNAR |
Tumor suppressor |
| miR-421 (54); miR-129, miR21, etc. |
Gastric juice |
Gastric malignancy |
Unknown |
Biomarkers for screening GC |
| miR-181b-5p (55) |
GC ascites exosome |
Promote EMT, peritoneal metastases |
Unknown |
Combine with CEA as a potential biomarker in malignant ascites |
